NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

阿茲海默症及帕金森氏症神經學的生物標記的全球市場

Neurological Biomarkers for Alzheimers and Parkinsons Diseases

出版商 Global Industry Analysts, Inc. 商品編碼 997514
出版日期 內容資訊 英文 108 Pages
商品交期: 最快1-2個工作天內
價格
阿茲海默症及帕金森氏症神經學的生物標記的全球市場 Neurological Biomarkers for Alzheimers and Parkinsons Diseases
出版日期: 2021年04月01日內容資訊: 英文 108 Pages
簡介

全球阿茲海默症及帕金森氏症神經學的生物標記的市場規模,預計在分析期間(2020年∼2027年)將以8.7%的年複合成長率增長,從2020年的46億美元,到2027年達到83億美元。

本報告提供全球阿茲海默症及帕金森氏症神經學的生物標記市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • AbaStar MDx
  • Abbott Laboratories
  • Abiant
  • Acumen Pharmaceuticals
  • Alseres Pharmaceuticals
  • Athena Diagnostics
  • Athena Diagnostics
  • Banyan Biomarkers
  • Bio-Rad Laboratories
  • Diagenic ASA
  • Immunarray Pvt. Ltd.
  • Myriad RBM
  • Proteome Sciences
  • ProteoSys AG
  • Psynova Neurotech
  • Qiagen
  • Quanterix Corporation
  • Thermo Fisher Scientific

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:46公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP13574

Abstract:

Global Neurological Biomarkers for Alzheimers and Parkinsons Diseases Market to Reach $8.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Neurological Biomarkers for Alzheimers and Parkinsons Diseases estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$8.3 Billion by 2027, growing at a CAGR of 8.7% over the period 2020-2027.

The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 8.1% CAGR

The Neurological Biomarkers for Alzheimers and Parkinsons Diseases market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 8.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.

Select Competitors (Total 46 Featured) -

  • AbaStar MDx
  • Abbott Laboratories
  • Abiant
  • Acumen Pharmaceuticals
  • Alseres Pharmaceuticals
  • Athena Diagnostics
  • Athena Diagnostics
  • Banyan Biomarkers
  • Bio-Rad Laboratories
  • Diagenic ASA
  • Immunarray Pvt. Ltd.
  • Myriad RBM
  • Proteome Sciences
  • ProteoSys AG
  • Psynova Neurotech
  • Qiagen
  • Quanterix Corporation
  • Thermo Fisher Scientific

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 4: USA Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 5: USA Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • CANADA
    • TABLE 6: Canada Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 7: Canada Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • JAPAN
    • TABLE 8: Japan Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 9: Japan Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • CHINA
    • TABLE 10: China Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 11: China Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • EUROPE
    • TABLE 12: Europe Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 13: Europe Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 14: Europe 15-Year Perspective for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 15: France Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 16: France Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • GERMANY
    • TABLE 17: Germany Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 18: Germany Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • ITALY
    • TABLE 19: Italy Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Italy Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • UNITED KINGDOM
    • TABLE 21: UK Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 22: UK Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • REST OF EUROPE
    • TABLE 23: Rest of Europe Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 24: Rest of Europe Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • ASIA-PACIFIC
    • TABLE 25: Asia-Pacific Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Asia-Pacific Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • REST OF WORLD
    • TABLE 27: Rest of World Current & Future Analysis for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 28: Rest of World Historic Review for Neurological Biomarkers for Alzheimers and Parkinsons Diseases by Segment - Neurological Biomarkers for Alzheimers and Parkinsons Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

IV. COMPETITION

  • Total Companies Profiled: 46